Increased	O
dissolution	B:C1285147
rates	O
of	O
tranilast	O
solid	O
dispersions	I:C3859614
extruded	O
with	O
inorganic	O
excipients	O
.	O

Increased	O
dissolution	O
rates	O
of	O
tranilast	O
solid	B:C3859614
dispersions	I:C3859614
extruded	O
with	O
inorganic	O
excipients	O
.	O

Increased	O
dissolution	O
rates	O
of	O
tranilast	O
solid	O
dispersions	I:C3859614
extruded	O
with	O
inorganic	O
excipients	B:C0015237
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	B:C3714234
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	B:C3714234
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	B:C0051515
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	B:C0013161
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	B:C0038891
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	B:C1099415
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	B:C0038891
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	B:C0146337
(	O
Tranilast	O
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	B:C0146337
)	O
-	O
based	O
solid	O
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
Neusilin	O
®	O
(	O
Neusilin	O
®	I:C3714234
)	O
a	O
synthetic	O
magnesium	O
aluminometasilicate	I:C0051515
as	O
an	O
inorganic	O
drug	O
carrier	I:C0013161
co-processed	O
with	O
the	O
hydrophilic	O
surfactants	O
Labrasol	O
and	O
Labrafil	O
to	O
develop	O
Tranilast	O
(	O
Tranilast	O
)	O
-	O
based	O
solid	B:C3859614
dispersions	I:C3859614
using	O
continuous	O
melt	O
extrusion	O
(	O
HME	O
)	O
processing	O
.	O

Twin	O
-	O
screw	O
extrusion	O
was	O
optimized	O
to	O
develop	O
various	O
Tranilast	B:C0146337
/	O
excipient	O
/	O
surfactant	O
formulations	O
followed	O
by	O
continuous	O
capsule	O
filling	O
in	O
the	O
absence	O
of	O
any	O
downstream	O
equipment	O
.	O

Twin	O
-	O
screw	O
extrusion	O
was	O
optimized	O
to	O
develop	O
various	O
Tranilast	O
/	O
excipient	B:C0015237
/	O
surfactant	O
formulations	O
followed	O
by	O
continuous	O
capsule	O
filling	O
in	O
the	O
absence	O
of	O
any	O
downstream	O
equipment	O
.	O

Twin	O
-	O
screw	O
extrusion	O
was	O
optimized	O
to	O
develop	O
various	O
Tranilast	O
/	O
excipient	O
/	O
surfactant	B:C0038891
formulations	O
followed	O
by	O
continuous	O
capsule	O
filling	O
in	O
the	O
absence	O
of	O
any	O
downstream	O
equipment	O
.	O

Twin	O
-	O
screw	O
extrusion	O
was	O
optimized	O
to	O
develop	O
various	O
Tranilast	O
/	O
excipient	O
/	O
surfactant	O
formulations	O
followed	O
by	O
continuous	O
capsule	B:C0006935
filling	O
in	O
the	O
absence	O
of	O
any	O
downstream	O
equipment	O
.	O

Twin	O
-	O
screw	O
extrusion	O
was	O
optimized	O
to	O
develop	O
various	O
Tranilast	O
/	O
excipient	O
/	O
surfactant	O
formulations	O
followed	O
by	O
continuous	O
capsule	O
filling	B:C3830127
in	O
the	O
absence	O
of	O
any	O
downstream	O
equipment	O
.	O

Physicochemical	O
characterization	O
showed	O
the	O
existence	O
of	O
Tranilast	B:C0146337
in	O
partially	O
crystalline	O
state	I:C0444626
in	O
the	O
porous	O
network	O
of	O
inorganic	O
NEU	I:C3714234
for	O
all	O
extruded	O
formulations	O
.	O

Physicochemical	O
characterization	O
showed	O
the	O
existence	O
of	O
Tranilast	O
in	O
partially	O
crystalline	B:C0444626
state	I:C0444626
in	O
the	O
porous	O
network	O
of	O
inorganic	O
NEU	I:C3714234
for	O
all	O
extruded	O
formulations	O
.	O

Physicochemical	O
characterization	O
showed	O
the	O
existence	O
of	O
Tranilast	O
in	O
partially	O
crystalline	O
state	I:C0444626
in	O
the	O
porous	O
network	O
of	O
inorganic	B:C3714234
NEU	I:C3714234
for	O
all	O
extruded	O
formulations	O
.	O

Furthermore	O
,	O
in	B:C0376519
-	I:C0376519
line	I:C0376519
NIR	I:C0376519
studies	I:C0376519
revealed	O
a	O
possible	O
intermolecular	O
H	O
-	O
bonding	O
formation	O
between	O
the	O
drug	O
and	O
the	O
carrier	O
resulting	O
in	O
the	O
increase	O
of	O
Tranilast	O
dissolution	O
rates	O
.	O

Furthermore	O
,	O
in	O
-	I:C0376519
line	I:C0376519
NIR	I:C0376519
studies	I:C0376519
revealed	O
a	O
possible	O
intermolecular	O
H	O
-	O
bonding	O
formation	O
between	O
the	O
drug	B:C1254351
and	O
the	O
carrier	O
resulting	O
in	O
the	O
increase	O
of	O
Tranilast	O
dissolution	O
rates	O
.	O

Furthermore	O
,	O
in	O
-	I:C0376519
line	I:C0376519
NIR	I:C0376519
studies	I:C0376519
revealed	O
a	O
possible	O
intermolecular	O
H	O
-	O
bonding	O
formation	O
between	O
the	O
drug	O
and	O
the	O
carrier	B:C0013161
resulting	O
in	O
the	O
increase	O
of	O
Tranilast	O
dissolution	O
rates	O
.	O

Furthermore	O
,	O
in	O
-	I:C0376519
line	I:C0376519
NIR	I:C0376519
studies	I:C0376519
revealed	O
a	O
possible	O
intermolecular	O
H	O
-	O
bonding	O
formation	O
between	O
the	O
drug	O
and	O
the	O
carrier	O
resulting	O
in	O
the	O
increase	O
of	O
Tranilast	B:C0146337
dissolution	O
rates	O
.	O

Furthermore	O
,	O
in	O
-	I:C0376519
line	I:C0376519
NIR	I:C0376519
studies	I:C0376519
revealed	O
a	O
possible	O
intermolecular	O
H	O
-	O
bonding	O
formation	O
between	O
the	O
drug	O
and	O
the	O
carrier	O
resulting	O
in	O
the	O
increase	O
of	O
Tranilast	O
dissolution	B:C1285147
rates	O
.	O

The	O
capsules	B:C0006935
containing	O
Tranilast	O
-	O
extruded	O
solid	O
dispersions	I:C3859614
showed	O
enhanced	O
dissolution	O
rates	O
and	O
compared	O
with	O
the	O
marketed	O
Rizaben	O
(	O
®	O
)	O
product	O
.	O

The	O
capsules	O
containing	O
Tranilast	B:C0146337
-	O
extruded	O
solid	O
dispersions	I:C3859614
showed	O
enhanced	O
dissolution	O
rates	O
and	O
compared	O
with	O
the	O
marketed	O
Rizaben	O
(	O
®	O
)	O
product	O
.	O

The	O
capsules	O
containing	O
Tranilast	O
-	O
extruded	O
solid	B:C3859614
dispersions	I:C3859614
showed	O
enhanced	O
dissolution	O
rates	O
and	O
compared	O
with	O
the	O
marketed	O
Rizaben	O
(	O
®	O
)	O
product	O
.	O

The	O
capsules	O
containing	O
Tranilast	O
-	O
extruded	O
solid	O
dispersions	I:C3859614
showed	O
enhanced	O
dissolution	B:C1285147
rates	O
and	O
compared	O
with	O
the	O
marketed	O
Rizaben	O
(	O
®	O
)	O
product	O
.	O

The	O
capsules	O
containing	O
Tranilast	O
-	O
extruded	O
solid	O
dispersions	I:C3859614
showed	O
enhanced	O
dissolution	O
rates	O
and	O
compared	O
with	O
the	O
marketed	O
Rizaben	B:C0282555
(	O
®	O
)	O
product	O
.	O

